Are you looking for the latest news in the business world? Well, you’ve come to the right place! At Extreme Investor Network, we pride ourselves on delivering unique and valuable information that will keep you ahead of the game. Today, we’re excited to share with you the FDA’s recent approval of Eli Lilly’s Alzheimer’s drug donanemab, now known as Kisunla.
Alzheimer’s disease is a devastating condition affecting nearly 7 million Americans, with that number expected to rise to almost 13 million by 2050. With limited treatment options available, the approval of Kisunla is a significant milestone in the fight against this mind-wasting disease.
Kisunla will be competing with another Alzheimer’s treatment called Leqembi, developed by Biogen and Eisai. Both drugs are monoclonal antibodies that target toxic plaques in the brain to slow the progression of Alzheimer’s in patients at the early stages of the disease.
In clinical trials, Eli Lilly’s drug showed a 35% slowing of Alzheimer’s progression compared to a placebo over 18 months. Patients were able to switch to a placebo after hitting certain goals for amyloid plaque clearance. However, it is important to note that neither Kisunla nor Leqembi is a cure for Alzheimer’s, and they come with potential safety risks, including severe side effects such as swelling and bleeding in the brain.
Kisunla will be administered through monthly infusions and is priced at $12,522 for a six-month course, $32,000 for 12 months, and $48,696 for 18 months. Medicare coverage and reimbursement options are available for eligible patients.
With the approval of Kisunla, Eli Lilly joins the ranks of companies working to combat Alzheimer’s disease, following the withdrawal of another therapy called Aduhelm. The FDA’s expedited approval of Aduhelm in 2021, despite a negative recommendation from an advisory panel, sparked criticism and raised important questions about the drug approval process.
Stay tuned to Extreme Investor Network for more in-depth coverage of the latest developments in the business world. Don’t miss out on valuable insights that will help you make informed investment decisions and stay ahead of the curve. Subscribe to our newsletter to receive exclusive content and expert analysis straight to your inbox.